Drug-Coated Balloons Expand Treatment Options
FDA approves blood pump system for patients undergoing high-risk PCI
Lipid Forum II Highlights
Best of Lipid Forum III
SAN DIEGO — At 12-month follow-up, autologous CD34+ cell therapy for patients with left ventricular dysfunction after STEMI appears to be safe and may be effective, according to new data from the PreSERVE-AMI study.
The cell therapy was safe and well tolerated, showed a signal of mortality benefit and showed a signal for reduced serious adverse events in higher-dose groups.
This activity is supported by an educational grant from AstraZeneca.
This activity is supported by an educational grant from Vivus, Inc.
Polypill could change secondary prevention strategies for US cardiologists
Treatment of VTE: Warfarin and parenteral anticoagulation still have a role
Appraisal of the National Lipid Association recommendations on cholesterol management
This feature offers timely executive summaries of the most relevant journals in cardiology.
Snapshot summaries of recent study results in cardiology.
Your central portal for information presented at ACC 2015.
Your resource for news and videos from SCAI 2014.
This exclusive Healio resource provides you a comprehensive window into what your colleagues and key opinion leaders are saying about current and future drugs and devices and their impact on patient outcomes.
Related story »
View past polls »
Search Healio's robust listing of national and international medical meetings.
©2015 All Rights Reserved.